New Research Reveals Promising Advances in Vision, Autoimmune Diseases, and Cancer Wasting Syndrome
Researchers at Cedars-Sinai Health Sciences University are leading groundbreaking studies that could open the door to new treatments for degenerative eye diseases, autoimmune disorders, and cancer-related wasting syndrome. The findings, recently published in scientific journals including Nature Communications and Cancers, provide important insights into how the body responds to complex diseases and how future therapies could improve patient outcomes.
Neural Stem Cells Show Promise in Preserving Vision
One of the most notable studies focuses on the use of transplanted neural stem cells as a potential treatment for retinitis pigmentosa, a degenerative retinal disease that leads to progressive vision loss.
Researchers discovered that neural stem cells can protect vision through several mechanisms. According to Clive Svendsen, PhD, executive director of the Board of Governors Regenerative Medicine Institute at Cedars-Sinai, the cells not only release protective proteins but also help restore retinal cells to a healthier state, reduce cellular stress, and maintain the structural integrity of the retina.
In the study, investigators transplanted neural stem cells into the retinas of laboratory rats experiencing retinal degeneration. Previous research showed that these transplants significantly reduced vision loss in the animals for up to 180 days, which researchers estimate is roughly equivalent to about 20 years in humans. In the latest study, scientists examined in greater detail how the transplanted cells interact with diseased retinal cells.
Shaomei Wang, MD, PhD, professor of Biomedical Sciences and co-corresponding author of the study, explained that the interaction between neural stem cells and retinal cells changes dynamically over time. Understanding this process could help scientists develop more effective treatments for degenerative eye diseases in the future.
A “Dimmer Switch” for the Immune System
In another Cedars-Sinai study, scientists identified a protein called Butyrophilin 2A2 (BTN2A2) that appears to act as a biological “dimmer switch,” helping regulate an overactive immune response.Experiments in laboratory mice showed that the absence of this protein triggered exaggerated immune reactions and increased kidney inflammation, a condition known as glomerulonephritis, which is one of the leading causes of chronic kidney disease worldwide.
When researchers introduced BTN2A2, they observed a significant reduction in inflammation, driven by an increase in immune-regulating T cells that help balance the body’s immune activity.
According to Ananth Karumanchi, MD, director of the Renovascular Research Center at Cedars-Sinai, the discovery could pave the way for new therapies targeting immune-driven diseases such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and even transplant rejection.
Detecting Early Signs of Cancer Wasting Syndrome
A third study conducted by Cedars-Sinai investigators examined cancer cachexia, also known as cancer wasting syndrome—a serious condition that causes severe weight loss, fatigue, and loss of muscle and fat in patients with advanced cancer.
Researchers analyzed blood samples from patients with advanced non-small cell lung cancer and discovered that specific biological markers change as cachexia progresses.Kamya Sankar, MD, co-medical director of the Thoracic Disease Research Group at Cedars-Sinai Cancer, explained that one key biomarker identified in early stages is an inflammatory protein called GDF-15, which is already being evaluated in clinical trials as a potential treatment target.
While larger studies are still needed to confirm these findings, researchers believe these biomarkers could help physicians identify patients at risk earlier and develop therapies to improve quality of life for people living with cancer.
